Articles By Jack Cush, MD
The Deadly Truth behind Paxil’s Study 329
Study 329 was published in 2001, and became a pivotal study for the anti-depressant drug Paxil (paroxetine). In 2002, over 2 million prescriptions were written for Paxil.
Read Article
Only 1 in 5 Seek Treatment for Raynaud's
October is Raynaud's Awareness Month according to the Raynaud's Association (http://www.raynauds.org), and a whopping 80 percent of sufferers are not aware they have the disorder and do not seek treatment.
Read Article
Increasing Numbers of Knee Replacements
Knee replacement surgery is on the rise, and so is the cost.
Read Article
Answering Patient Emails
A recent article by Dr. Joseph Eastern of the Pediatric News Network addressed an issue that confronts all practitioners - how do you handle email from patients?
Read Article
Fibromyalgia Prevalence & Characteristics
PLOS has reported the results of the 2012 US National Health Interview Survey that focuses on fibromyalgia.
Read Article
PLLR - The Pregnancy & Lactation Labeling Rule Explained
A recent article from Healio.com reviewed the FDA’s Pregnancy and Lactation Labeling Rule (PLLR) that became effective June 30th.
Read Article
Marketing 101
Why let your practice mix grow according to word-of-mouth, preferred provider listings and beauty parlor gossip? Be all you can be with a marketing plan for your practice and career.
Read Article
DATA-Switch Study Finds the Right Sequence to Building Better Bone Mass
Long-term management of osteoporosis can be challenging, and given the increasing number of choices, the best sequence of drug use has not been addressed adequately.
Read Article
Future 2 Trial Shows Secukinumab Efficacy in Psoriatic Arthritis
Secukinumab (Cosentyx) is an anti-IL-17 monoclonal antibody currently approved for use in moderate to severe psoriasis. It has also been studied in psoriatic arthritis (PsA) and shown to be safe and effective.
Read Article
DAS28-CRP or DAS28-ESR: Are they Biosimilar?
The disease activity score (DAS28) has been developed as a dynamic assessment tool and a therapeutic response measure for use in clinical trials and practice.
Read Article
